Cytochrome P450 3A Inhibition by Ketoconazole Affects Prasugrel and Clopidogrel Pharmacokinetics and Pharmacodynamics Differently View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

2007-05

AUTHORS

N A Farid, C D Payne, D S Small, K J Winters, C S Ernest, J T Brandt, C Darstein, J A Jakubowski, D E Salazar

ABSTRACT

Prasugrel and clopidogrel inhibit platelet aggregation through active metabolite formation. Prasugrel's active metabolite (R-138727) is formed primarily by cytochrome P450 (CYP) 3A and CYP2B6, with roles for CYP2C9 and CYP2C19. Clopidogrel's activation involves two sequential steps by CYP3A, CYP1A2, CYP2C9, CYP2C19, and/or CYP2B6. In a randomized crossover study, healthy subjects received a loading dose (LD) of prasugrel (60 mg) or clopidogrel (300 mg), followed by five daily maintenance doses (MDs) (15 and 75 mg, respectively) with or without the potent CYP3A inhibitor ketoconazole (400 mg/day). Subjects had a 2-week washout between periods. Ketoconazole decreased R-138727 and clopidogrel active metabolite Cmax (maximum plasma concentration) 34-61% after prasugrel and clopidogrel dosing. Ketoconazole did not affect R-138727 exposure or prasugrel's inhibition of platelet aggregation (IPA). Ketoconazole decreased clopidogrel's active metabolite AUC0-24 (area under the concentration-time curve to 24 h postdose) 22% (LD) to 29% (MD) and reduced IPA 28% (LD) to 33% (MD). We conclude that CYP3A4 and CYP3A5 inhibition by ketoconazole affects formation of clopidogrel's but not prasugrel's active metabolite. The decreased formation of clopidogrel's active metabolite is associated with reduced IPA. More... »

PAGES

735-741

Identifiers

URI

http://scigraph.springernature.com/pub.10.1038/sj.clpt.6100139

DOI

http://dx.doi.org/10.1038/sj.clpt.6100139

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1006304268

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/17361128


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1115", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Pharmacology and Pharmaceutical Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Adult", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Area Under Curve", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Clopidogrel", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Cross-Over Studies", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Cytochrome P-450 CYP3A Inhibitors", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Double-Blind Method", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Drug Interactions", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Enzyme Inhibitors", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Female", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Ketoconazole", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Male", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Middle Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Piperazines", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Platelet Aggregation", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Platelet Aggregation Inhibitors", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Prasugrel Hydrochloride", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Thiophenes", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Ticlopidine", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Eli Lilly (United States)", 
          "id": "https://www.grid.ac/institutes/grid.417540.3", 
          "name": [
            "Lilly Research Laboratories, Eli Lilly and Company Indianapolis Indiana USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Farid", 
        "givenName": "N A", 
        "id": "sg:person.01255414044.69", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01255414044.69"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "name": [
            "Lilly Research Center Ltd Windlesham UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Payne", 
        "givenName": "C D", 
        "id": "sg:person.01224546355.86", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01224546355.86"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Eli Lilly (United States)", 
          "id": "https://www.grid.ac/institutes/grid.417540.3", 
          "name": [
            "Lilly Research Laboratories, Eli Lilly and Company Indianapolis Indiana USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Small", 
        "givenName": "D S", 
        "id": "sg:person.01126325126.28", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01126325126.28"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Eli Lilly (United States)", 
          "id": "https://www.grid.ac/institutes/grid.417540.3", 
          "name": [
            "Lilly Research Laboratories, Eli Lilly and Company Indianapolis Indiana USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Winters", 
        "givenName": "K J", 
        "id": "sg:person.01046045655.15", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01046045655.15"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Eli Lilly (United States)", 
          "id": "https://www.grid.ac/institutes/grid.417540.3", 
          "name": [
            "Lilly Research Laboratories, Eli Lilly and Company Indianapolis Indiana USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Ernest", 
        "givenName": "C S", 
        "id": "sg:person.01252000221.39", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01252000221.39"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Eli Lilly (United States)", 
          "id": "https://www.grid.ac/institutes/grid.417540.3", 
          "name": [
            "Lilly Research Laboratories, Eli Lilly and Company Indianapolis Indiana USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Brandt", 
        "givenName": "J T", 
        "id": "sg:person.01340774755.46", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01340774755.46"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Eli Lilly (United States)", 
          "id": "https://www.grid.ac/institutes/grid.417540.3", 
          "name": [
            "Lilly Research Laboratories, Eli Lilly and Company Indianapolis Indiana USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Darstein", 
        "givenName": "C", 
        "id": "sg:person.01137756171.46", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01137756171.46"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Eli Lilly (United States)", 
          "id": "https://www.grid.ac/institutes/grid.417540.3", 
          "name": [
            "Lilly Research Laboratories, Eli Lilly and Company Indianapolis Indiana USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Jakubowski", 
        "givenName": "J A", 
        "id": "sg:person.0756623644.24", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0756623644.24"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Daiichi Sankyo (United States)", 
          "id": "https://www.grid.ac/institutes/grid.428496.5", 
          "name": [
            "Daiichi Sankyo Inc. Parsippany New Jersey USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Salazar", 
        "givenName": "D E", 
        "id": "sg:person.014714657504.26", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.014714657504.26"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "https://doi.org/10.1161/01.cir.0000047060.60595.cc", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1010854770"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1182/blood-2002-10-3027", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1014797573"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1503/cmaj.060664", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1016886879"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1503/cmaj.060664", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1016886879"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1111/j.1365-2141.1985.tb07467.x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1030449319"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1093/eurheartj/ehi877", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1033526755"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1124/dmd.31.7.815", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1034066953"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1182/blood-2006-04-013052", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1034582023"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1161/01.cir.0000112378.09325.f9", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1037144438"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1124/dmd.105.007989", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1038051799"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1124/dmd.31.1.53", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1040947861"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1038/sj.bjp.0703237", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1041733321"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1056/nejmoa010746", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1042739677"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.amjcard.2006.09.078", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1050252358"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1161/01.cir.0000099507.32936.c0", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1051697653"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1111/j.1742-7843.2005.pto960203.x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1052432532"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1002/rcm.2813", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1052975930"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.ahj.2006.10.010", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1053653581"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s0195-668x(03)00442-1", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1054625464"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1055/s-0037-1614133", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1074741659"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1055/s-0037-1613462", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1075277395"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2007-05", 
    "datePublishedReg": "2007-05-01", 
    "description": "Prasugrel and clopidogrel inhibit platelet aggregation through active metabolite formation. Prasugrel's active metabolite (R-138727) is formed primarily by cytochrome P450 (CYP) 3A and CYP2B6, with roles for CYP2C9 and CYP2C19. Clopidogrel's activation involves two sequential steps by CYP3A, CYP1A2, CYP2C9, CYP2C19, and/or CYP2B6. In a randomized crossover study, healthy subjects received a loading dose (LD) of prasugrel (60 mg) or clopidogrel (300 mg), followed by five daily maintenance doses (MDs) (15 and 75 mg, respectively) with or without the potent CYP3A inhibitor ketoconazole (400 mg/day). Subjects had a 2-week washout between periods. Ketoconazole decreased R-138727 and clopidogrel active metabolite Cmax (maximum plasma concentration) 34-61% after prasugrel and clopidogrel dosing. Ketoconazole did not affect R-138727 exposure or prasugrel's inhibition of platelet aggregation (IPA). Ketoconazole decreased clopidogrel's active metabolite AUC0-24 (area under the concentration-time curve to 24 h postdose) 22% (LD) to 29% (MD) and reduced IPA 28% (LD) to 33% (MD). We conclude that CYP3A4 and CYP3A5 inhibition by ketoconazole affects formation of clopidogrel's but not prasugrel's active metabolite. The decreased formation of clopidogrel's active metabolite is associated with reduced IPA.", 
    "genre": "research_article", 
    "id": "sg:pub.10.1038/sj.clpt.6100139", 
    "inLanguage": [
      "en"
    ], 
    "isAccessibleForFree": false, 
    "isPartOf": [
      {
        "id": "sg:journal.1017409", 
        "issn": [
          "0009-9236", 
          "1532-6535"
        ], 
        "name": "Clinical Pharmacology & Therapeutics", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "5", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "81"
      }
    ], 
    "name": "Cytochrome P450 3A Inhibition by Ketoconazole Affects Prasugrel and Clopidogrel Pharmacokinetics and Pharmacodynamics Differently", 
    "pagination": "735-741", 
    "productId": [
      {
        "name": "readcube_id", 
        "type": "PropertyValue", 
        "value": [
          "1e078ce93f9c4d8e2c19caf286e610f45deca7bc76978a12918b6e7371d5e00a"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "17361128"
        ]
      }, 
      {
        "name": "nlm_unique_id", 
        "type": "PropertyValue", 
        "value": [
          "0372741"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1038/sj.clpt.6100139"
        ]
      }, 
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1006304268"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1038/sj.clpt.6100139", 
      "https://app.dimensions.ai/details/publication/pub.1006304268"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2019-04-11T13:00", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-uberresearch-data-dimensions-target-20181106-alternative/cleanup/v134/2549eaecd7973599484d7c17b260dba0a4ecb94b/merge/v9/a6c9fde33151104705d4d7ff012ea9563521a3ce/jats-lookup/v90/0000000365_0000000365/records_71704_00000000.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "http://onlinelibrary.wiley.com/doi/10.1038/sj.clpt.6100139/abstract"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1038/sj.clpt.6100139'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1038/sj.clpt.6100139'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1038/sj.clpt.6100139'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1038/sj.clpt.6100139'


 

This table displays all metadata directly associated to this object as RDF triples.

266 TRIPLES      21 PREDICATES      68 URIs      40 LITERALS      28 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1038/sj.clpt.6100139 schema:about N096d659b22f64c09ac0e32482c46b4c9
2 N388787f4cb054820b22ab3e09172b411
3 N3a6ee08dbb684a038499786158093779
4 N3cb18e7fa4fe47c79a552dd1c01eaa47
5 N574ca67aad064ca0bd9334cfc3beb48c
6 N650f28d86b7f4a1bbc053326d2aa0a0a
7 N6ecafac6c4f54ffbabb4e42e404c0f17
8 N87ce5a7832f94e01b3f171ecfd445cef
9 N89c832d6dab24405ae318c81fc51c52d
10 Na9977fe2e7a94678b8b88db4235bcfc1
11 Nac4f5adf044d4ac6870236f7d6a560d8
12 Nb1cd74906745499599512c39e0cb1d31
13 Nc603c9f0f9a644e9b2fd1a9e2a721a1a
14 Nca8069c49ada40d9bf3a6a6fa2d52230
15 Ncd17b42aa5e240b4a397f7d0ea58feae
16 Nd688998ec6004c838b82652ac40a283d
17 Ne238decdd7cf4265a06ea708a33164f0
18 Nee1be38e3cbf41d4860b8d76aefd596e
19 Nef935094a251457f9e835d16040cc06c
20 anzsrc-for:11
21 anzsrc-for:1115
22 schema:author N0ae205c77ddb4aa99cad746d0d3fd98a
23 schema:citation https://doi.org/10.1002/rcm.2813
24 https://doi.org/10.1016/j.ahj.2006.10.010
25 https://doi.org/10.1016/j.amjcard.2006.09.078
26 https://doi.org/10.1016/s0195-668x(03)00442-1
27 https://doi.org/10.1038/sj.bjp.0703237
28 https://doi.org/10.1055/s-0037-1613462
29 https://doi.org/10.1055/s-0037-1614133
30 https://doi.org/10.1056/nejmoa010746
31 https://doi.org/10.1093/eurheartj/ehi877
32 https://doi.org/10.1111/j.1365-2141.1985.tb07467.x
33 https://doi.org/10.1111/j.1742-7843.2005.pto960203.x
34 https://doi.org/10.1124/dmd.105.007989
35 https://doi.org/10.1124/dmd.31.1.53
36 https://doi.org/10.1124/dmd.31.7.815
37 https://doi.org/10.1161/01.cir.0000047060.60595.cc
38 https://doi.org/10.1161/01.cir.0000099507.32936.c0
39 https://doi.org/10.1161/01.cir.0000112378.09325.f9
40 https://doi.org/10.1182/blood-2002-10-3027
41 https://doi.org/10.1182/blood-2006-04-013052
42 https://doi.org/10.1503/cmaj.060664
43 schema:datePublished 2007-05
44 schema:datePublishedReg 2007-05-01
45 schema:description Prasugrel and clopidogrel inhibit platelet aggregation through active metabolite formation. Prasugrel's active metabolite (R-138727) is formed primarily by cytochrome P450 (CYP) 3A and CYP2B6, with roles for CYP2C9 and CYP2C19. Clopidogrel's activation involves two sequential steps by CYP3A, CYP1A2, CYP2C9, CYP2C19, and/or CYP2B6. In a randomized crossover study, healthy subjects received a loading dose (LD) of prasugrel (60 mg) or clopidogrel (300 mg), followed by five daily maintenance doses (MDs) (15 and 75 mg, respectively) with or without the potent CYP3A inhibitor ketoconazole (400 mg/day). Subjects had a 2-week washout between periods. Ketoconazole decreased R-138727 and clopidogrel active metabolite Cmax (maximum plasma concentration) 34-61% after prasugrel and clopidogrel dosing. Ketoconazole did not affect R-138727 exposure or prasugrel's inhibition of platelet aggregation (IPA). Ketoconazole decreased clopidogrel's active metabolite AUC0-24 (area under the concentration-time curve to 24 h postdose) 22% (LD) to 29% (MD) and reduced IPA 28% (LD) to 33% (MD). We conclude that CYP3A4 and CYP3A5 inhibition by ketoconazole affects formation of clopidogrel's but not prasugrel's active metabolite. The decreased formation of clopidogrel's active metabolite is associated with reduced IPA.
46 schema:genre research_article
47 schema:inLanguage en
48 schema:isAccessibleForFree false
49 schema:isPartOf N11b0006b48f24d97960ca568962ee31f
50 N54f433ffaa874002904cad0c9960eb4f
51 sg:journal.1017409
52 schema:name Cytochrome P450 3A Inhibition by Ketoconazole Affects Prasugrel and Clopidogrel Pharmacokinetics and Pharmacodynamics Differently
53 schema:pagination 735-741
54 schema:productId N0bc17a1fe34a483c822e947cfa4b9bbe
55 N0d9efc7849ed43e4ada920abb05cf5da
56 N9c4bbe482a06405c8884343b819d0f12
57 Ndb18a0cc3c7f4f548b899389c8605a1c
58 Nffdf0aaeb04e406cba6a1c65729a5adb
59 schema:sameAs https://app.dimensions.ai/details/publication/pub.1006304268
60 https://doi.org/10.1038/sj.clpt.6100139
61 schema:sdDatePublished 2019-04-11T13:00
62 schema:sdLicense https://scigraph.springernature.com/explorer/license/
63 schema:sdPublisher N580757bf7f404c02bc71600ae43a22dd
64 schema:url http://onlinelibrary.wiley.com/doi/10.1038/sj.clpt.6100139/abstract
65 sgo:license sg:explorer/license/
66 sgo:sdDataset articles
67 rdf:type schema:ScholarlyArticle
68 N096d659b22f64c09ac0e32482c46b4c9 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
69 schema:name Platelet Aggregation
70 rdf:type schema:DefinedTerm
71 N0ae205c77ddb4aa99cad746d0d3fd98a rdf:first sg:person.01255414044.69
72 rdf:rest Nf64ded85581746d0a518312564ff1d1e
73 N0bc17a1fe34a483c822e947cfa4b9bbe schema:name pubmed_id
74 schema:value 17361128
75 rdf:type schema:PropertyValue
76 N0d9efc7849ed43e4ada920abb05cf5da schema:name dimensions_id
77 schema:value pub.1006304268
78 rdf:type schema:PropertyValue
79 N0f9b33a6a1ef48b489a33919f7d0202e rdf:first sg:person.01046045655.15
80 rdf:rest Nf69e8954c2164f318b17f63f5ccc3890
81 N11b0006b48f24d97960ca568962ee31f schema:issueNumber 5
82 rdf:type schema:PublicationIssue
83 N33665fec378e43a8a653fc1ff2b3de3d schema:name Lilly Research Center Ltd Windlesham UK
84 rdf:type schema:Organization
85 N361fcd22e66345e3be83594b8db77efe rdf:first sg:person.014714657504.26
86 rdf:rest rdf:nil
87 N388787f4cb054820b22ab3e09172b411 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
88 schema:name Humans
89 rdf:type schema:DefinedTerm
90 N3a6ee08dbb684a038499786158093779 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
91 schema:name Cross-Over Studies
92 rdf:type schema:DefinedTerm
93 N3cb18e7fa4fe47c79a552dd1c01eaa47 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
94 schema:name Platelet Aggregation Inhibitors
95 rdf:type schema:DefinedTerm
96 N3f4a4a34d8824f929573cc31989db188 rdf:first sg:person.01126325126.28
97 rdf:rest N0f9b33a6a1ef48b489a33919f7d0202e
98 N54f433ffaa874002904cad0c9960eb4f schema:volumeNumber 81
99 rdf:type schema:PublicationVolume
100 N574ca67aad064ca0bd9334cfc3beb48c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
101 schema:name Thiophenes
102 rdf:type schema:DefinedTerm
103 N580757bf7f404c02bc71600ae43a22dd schema:name Springer Nature - SN SciGraph project
104 rdf:type schema:Organization
105 N650f28d86b7f4a1bbc053326d2aa0a0a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
106 schema:name Middle Aged
107 rdf:type schema:DefinedTerm
108 N688079cf00974dd797e81aa7da22e40c rdf:first sg:person.01137756171.46
109 rdf:rest N97418019f3974013a9c2efbbedc1d07b
110 N6ecafac6c4f54ffbabb4e42e404c0f17 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
111 schema:name Piperazines
112 rdf:type schema:DefinedTerm
113 N87ce5a7832f94e01b3f171ecfd445cef schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
114 schema:name Double-Blind Method
115 rdf:type schema:DefinedTerm
116 N89c832d6dab24405ae318c81fc51c52d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
117 schema:name Prasugrel Hydrochloride
118 rdf:type schema:DefinedTerm
119 N97418019f3974013a9c2efbbedc1d07b rdf:first sg:person.0756623644.24
120 rdf:rest N361fcd22e66345e3be83594b8db77efe
121 N9c4bbe482a06405c8884343b819d0f12 schema:name doi
122 schema:value 10.1038/sj.clpt.6100139
123 rdf:type schema:PropertyValue
124 Na9977fe2e7a94678b8b88db4235bcfc1 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
125 schema:name Female
126 rdf:type schema:DefinedTerm
127 Nac4f5adf044d4ac6870236f7d6a560d8 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
128 schema:name Cytochrome P-450 CYP3A Inhibitors
129 rdf:type schema:DefinedTerm
130 Nb1cd74906745499599512c39e0cb1d31 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
131 schema:name Ticlopidine
132 rdf:type schema:DefinedTerm
133 Nc603c9f0f9a644e9b2fd1a9e2a721a1a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
134 schema:name Clopidogrel
135 rdf:type schema:DefinedTerm
136 Nca8069c49ada40d9bf3a6a6fa2d52230 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
137 schema:name Drug Interactions
138 rdf:type schema:DefinedTerm
139 Ncd17b42aa5e240b4a397f7d0ea58feae schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
140 schema:name Ketoconazole
141 rdf:type schema:DefinedTerm
142 Nd688998ec6004c838b82652ac40a283d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
143 schema:name Area Under Curve
144 rdf:type schema:DefinedTerm
145 Ndb18a0cc3c7f4f548b899389c8605a1c schema:name nlm_unique_id
146 schema:value 0372741
147 rdf:type schema:PropertyValue
148 Ne238decdd7cf4265a06ea708a33164f0 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
149 schema:name Enzyme Inhibitors
150 rdf:type schema:DefinedTerm
151 Ned35156fabab46daadf89ff8a1dfed6a rdf:first sg:person.01340774755.46
152 rdf:rest N688079cf00974dd797e81aa7da22e40c
153 Nee1be38e3cbf41d4860b8d76aefd596e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
154 schema:name Male
155 rdf:type schema:DefinedTerm
156 Nef935094a251457f9e835d16040cc06c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
157 schema:name Adult
158 rdf:type schema:DefinedTerm
159 Nf64ded85581746d0a518312564ff1d1e rdf:first sg:person.01224546355.86
160 rdf:rest N3f4a4a34d8824f929573cc31989db188
161 Nf69e8954c2164f318b17f63f5ccc3890 rdf:first sg:person.01252000221.39
162 rdf:rest Ned35156fabab46daadf89ff8a1dfed6a
163 Nffdf0aaeb04e406cba6a1c65729a5adb schema:name readcube_id
164 schema:value 1e078ce93f9c4d8e2c19caf286e610f45deca7bc76978a12918b6e7371d5e00a
165 rdf:type schema:PropertyValue
166 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
167 schema:name Medical and Health Sciences
168 rdf:type schema:DefinedTerm
169 anzsrc-for:1115 schema:inDefinedTermSet anzsrc-for:
170 schema:name Pharmacology and Pharmaceutical Sciences
171 rdf:type schema:DefinedTerm
172 sg:journal.1017409 schema:issn 0009-9236
173 1532-6535
174 schema:name Clinical Pharmacology & Therapeutics
175 rdf:type schema:Periodical
176 sg:person.01046045655.15 schema:affiliation https://www.grid.ac/institutes/grid.417540.3
177 schema:familyName Winters
178 schema:givenName K J
179 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01046045655.15
180 rdf:type schema:Person
181 sg:person.01126325126.28 schema:affiliation https://www.grid.ac/institutes/grid.417540.3
182 schema:familyName Small
183 schema:givenName D S
184 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01126325126.28
185 rdf:type schema:Person
186 sg:person.01137756171.46 schema:affiliation https://www.grid.ac/institutes/grid.417540.3
187 schema:familyName Darstein
188 schema:givenName C
189 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01137756171.46
190 rdf:type schema:Person
191 sg:person.01224546355.86 schema:affiliation N33665fec378e43a8a653fc1ff2b3de3d
192 schema:familyName Payne
193 schema:givenName C D
194 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01224546355.86
195 rdf:type schema:Person
196 sg:person.01252000221.39 schema:affiliation https://www.grid.ac/institutes/grid.417540.3
197 schema:familyName Ernest
198 schema:givenName C S
199 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01252000221.39
200 rdf:type schema:Person
201 sg:person.01255414044.69 schema:affiliation https://www.grid.ac/institutes/grid.417540.3
202 schema:familyName Farid
203 schema:givenName N A
204 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01255414044.69
205 rdf:type schema:Person
206 sg:person.01340774755.46 schema:affiliation https://www.grid.ac/institutes/grid.417540.3
207 schema:familyName Brandt
208 schema:givenName J T
209 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01340774755.46
210 rdf:type schema:Person
211 sg:person.014714657504.26 schema:affiliation https://www.grid.ac/institutes/grid.428496.5
212 schema:familyName Salazar
213 schema:givenName D E
214 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.014714657504.26
215 rdf:type schema:Person
216 sg:person.0756623644.24 schema:affiliation https://www.grid.ac/institutes/grid.417540.3
217 schema:familyName Jakubowski
218 schema:givenName J A
219 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0756623644.24
220 rdf:type schema:Person
221 https://doi.org/10.1002/rcm.2813 schema:sameAs https://app.dimensions.ai/details/publication/pub.1052975930
222 rdf:type schema:CreativeWork
223 https://doi.org/10.1016/j.ahj.2006.10.010 schema:sameAs https://app.dimensions.ai/details/publication/pub.1053653581
224 rdf:type schema:CreativeWork
225 https://doi.org/10.1016/j.amjcard.2006.09.078 schema:sameAs https://app.dimensions.ai/details/publication/pub.1050252358
226 rdf:type schema:CreativeWork
227 https://doi.org/10.1016/s0195-668x(03)00442-1 schema:sameAs https://app.dimensions.ai/details/publication/pub.1054625464
228 rdf:type schema:CreativeWork
229 https://doi.org/10.1038/sj.bjp.0703237 schema:sameAs https://app.dimensions.ai/details/publication/pub.1041733321
230 rdf:type schema:CreativeWork
231 https://doi.org/10.1055/s-0037-1613462 schema:sameAs https://app.dimensions.ai/details/publication/pub.1075277395
232 rdf:type schema:CreativeWork
233 https://doi.org/10.1055/s-0037-1614133 schema:sameAs https://app.dimensions.ai/details/publication/pub.1074741659
234 rdf:type schema:CreativeWork
235 https://doi.org/10.1056/nejmoa010746 schema:sameAs https://app.dimensions.ai/details/publication/pub.1042739677
236 rdf:type schema:CreativeWork
237 https://doi.org/10.1093/eurheartj/ehi877 schema:sameAs https://app.dimensions.ai/details/publication/pub.1033526755
238 rdf:type schema:CreativeWork
239 https://doi.org/10.1111/j.1365-2141.1985.tb07467.x schema:sameAs https://app.dimensions.ai/details/publication/pub.1030449319
240 rdf:type schema:CreativeWork
241 https://doi.org/10.1111/j.1742-7843.2005.pto960203.x schema:sameAs https://app.dimensions.ai/details/publication/pub.1052432532
242 rdf:type schema:CreativeWork
243 https://doi.org/10.1124/dmd.105.007989 schema:sameAs https://app.dimensions.ai/details/publication/pub.1038051799
244 rdf:type schema:CreativeWork
245 https://doi.org/10.1124/dmd.31.1.53 schema:sameAs https://app.dimensions.ai/details/publication/pub.1040947861
246 rdf:type schema:CreativeWork
247 https://doi.org/10.1124/dmd.31.7.815 schema:sameAs https://app.dimensions.ai/details/publication/pub.1034066953
248 rdf:type schema:CreativeWork
249 https://doi.org/10.1161/01.cir.0000047060.60595.cc schema:sameAs https://app.dimensions.ai/details/publication/pub.1010854770
250 rdf:type schema:CreativeWork
251 https://doi.org/10.1161/01.cir.0000099507.32936.c0 schema:sameAs https://app.dimensions.ai/details/publication/pub.1051697653
252 rdf:type schema:CreativeWork
253 https://doi.org/10.1161/01.cir.0000112378.09325.f9 schema:sameAs https://app.dimensions.ai/details/publication/pub.1037144438
254 rdf:type schema:CreativeWork
255 https://doi.org/10.1182/blood-2002-10-3027 schema:sameAs https://app.dimensions.ai/details/publication/pub.1014797573
256 rdf:type schema:CreativeWork
257 https://doi.org/10.1182/blood-2006-04-013052 schema:sameAs https://app.dimensions.ai/details/publication/pub.1034582023
258 rdf:type schema:CreativeWork
259 https://doi.org/10.1503/cmaj.060664 schema:sameAs https://app.dimensions.ai/details/publication/pub.1016886879
260 rdf:type schema:CreativeWork
261 https://www.grid.ac/institutes/grid.417540.3 schema:alternateName Eli Lilly (United States)
262 schema:name Lilly Research Laboratories, Eli Lilly and Company Indianapolis Indiana USA
263 rdf:type schema:Organization
264 https://www.grid.ac/institutes/grid.428496.5 schema:alternateName Daiichi Sankyo (United States)
265 schema:name Daiichi Sankyo Inc. Parsippany New Jersey USA
266 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...